Effects of Mindfulness Meditation in Virtual Reality on Craving and Smoking Cessation

Launched by CENTRE HOSPITALIER HENRI LABORIT · Mar 10, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of mindfulness meditation using virtual reality to help people quit smoking. Researchers believe that practicing mindfulness in a virtual setting can reduce the strong urges to smoke and help prevent relapse, or returning to smoking, after quitting. Participants in the study will be divided into two groups: one group will experience six weekly virtual reality meditation sessions, while the other group will receive standard treatment with nicotine patches and gum.

To join the trial, you need to be between 18 and 75 years old and currently smoke 10 to 40 cigarettes a day. You should also have a diagnosis of tobacco use disorder but should not have severe mental health issues or other serious medical conditions. If you participate, you will attend follow-up visits at three and six months to see if you have been able to stay smoke-free. This study offers an innovative approach to smoking cessation that could benefit many individuals looking to quit.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Any patient consuming 10 to 40 cigarettes per day
• • Woman or man aged 18 to 75 inclusive
• • Substance use disorder according to the DSM5 classification
• • Benefit from social security or benefit from it through a third party in accordance with French law on research involving the human person
• • Having signed the informed consent form after having received written information.
• Exclusion Criteria:
• • Disabling cognitive disorders
• • Patient under 18 or over 75 years old.
• • Patient with a psychological disorder or a psychiatric pathology requiring specialized follow-up
• • Patient with addiction to another product.
• • Cardiological pathologies that could compromise the participation of patients, detected by an ECG (only for patients who will be randomized in the experimental group).
• • Advanced pulmonary, renal, and hepatic diseases, or any unstable and serious medical conditions that could compromise the patient's participation in the study, subject to the judgment of the doctor
• • Pregnant or breastfeeding woman
• • Simultaneous participation in another trial
• • Employee of the investigator or of the clinical trial site
• • Patients protected by law
• • Patients who do not speak the French language
• • People not covered by state health insurance
• • Patients who in the opinion of the investigator are unable to complete the questionnaires
• • Patient claustrophobic or anxious about using the cabin
• • Patient allergic to a molecule present in nicotine substitutes